-
Active Trials
-
Phase 3
-
Phase 2
-
Phase 1
-
Results Pending
📊
Pipeline Summary
Expected Approvals
FDA Decisions 4 upcoming PDUFA dates
Welireg (belzutifan) + Keytruda (pembrolizumab) Adjuvant clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence sNDA + sBLA
Winrevair (sotatercept) Recently diagnosed pulmonary arterial hypertension (PAH, HYPERION label update) sBLA
Welireg (belzutifan) + Lenvima (lenvatinib) Previously treated advanced ccRCC post-PD-1/PD-L1 therapy sNDA
Ifinatamab deruxtecan (I-DXd) Extensive-stage small cell lung cancer (ES-SCLC) after platinum chemo BLA
Clinical Trials
Loading...